secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001564590-21-056179
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reports positive Phase 1b/2a results for ATYR1923; Q3 cash $116.4M
------------------------------------------------------------------------------

- Positive proof-of-concept data for ATYR1923 in pulmonary sarcoidosis; registrational trial expected in 2022.
- Cash, cash equivalents and investments $116.4M at Sept 30, 2021, after $80.6M net from stock offering.
- R&D expenses $5.1M and G&A $2.6M for Q3 2021; 27.8M shares outstanding.
- Appointed Robert W. Ashworth, PhD, as VP of Regulatory Affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459021056179/0001564590-21-056179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459021056179/life-8k_20211110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer